Key Takeaways Alcon's Surgical unit grew 2% in Q2, aided by consumables strength and new product launches. ALC's Vision Care is fueled by contact lens advances, FDA approval of TRYPTYR, and strong eye drop sales. Macroeconomic headwinds, tariffs, and rising costs weighed on Alcon's Q2 results and outlook. Alcon’s (ALC) Vision Care business continues to gain from its diverse portfolio of contact lenses and ocular health products. Additionally, growth momentum within the Surgical business is poised to boost t ...